Sumitomo Dainippon Pharma Stock Net Income
DNPUFDelisted Stock | USD 4.37 0.00 0.00% |
Sumitomo Dainippon Pharma fundamentals help investors to digest information that contributes to Sumitomo Dainippon's financial success or failures. It also enables traders to predict the movement of Sumitomo Pink Sheet. The fundamental analysis module provides a way to measure Sumitomo Dainippon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sumitomo Dainippon pink sheet.
Sumitomo |
Sumitomo Dainippon Pharma Company Net Income Analysis
Sumitomo Dainippon's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Sumitomo Dainippon Net Income | 56.41 B |
Most of Sumitomo Dainippon's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sumitomo Dainippon Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Sumitomo Dainippon Pharma reported net income of 56.41 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is significantly lower than that of the firm.
Sumitomo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sumitomo Dainippon's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sumitomo Dainippon could also be used in its relative valuation, which is a method of valuing Sumitomo Dainippon by comparing valuation metrics of similar companies.Sumitomo Dainippon is currently under evaluation in net income category among its peers.
Sumitomo Fundamentals
Return On Equity | -0.0399 | |||
Return On Asset | -0.0075 | |||
Profit Margin | (0.01) % | |||
Operating Margin | (0.03) % | |||
Current Valuation | 2.85 B | |||
Shares Outstanding | 397.29 M | |||
Shares Owned By Insiders | 58.59 % | |||
Shares Owned By Institutions | 19.60 % | |||
Price To Earning | 4.79 X | |||
Price To Book | 0.64 X | |||
Price To Sales | 0.01 X | |||
Revenue | 560.03 B | |||
Gross Profit | 402.91 B | |||
EBITDA | 124.36 B | |||
Net Income | 56.41 B | |||
Cash And Equivalents | 265.59 B | |||
Cash Per Share | 668.50 X | |||
Total Debt | 243.96 B | |||
Debt To Equity | 0.36 % | |||
Current Ratio | 1.74 X | |||
Book Value Per Share | 1,599 X | |||
Cash Flow From Operations | 31.24 B | |||
Earnings Per Share | 0.24 X | |||
Number Of Employees | 6.99 K | |||
Beta | 0.31 | |||
Market Capitalization | 2.64 B | |||
Total Asset | 1.31 T | |||
Retained Earnings | 349.13 B | |||
Working Capital | 224.66 B | |||
Current Asset | 384.35 B | |||
Current Liabilities | 159.68 B | |||
Annual Yield | 0.03 % | |||
Net Asset | 1.31 T | |||
Last Dividend Paid | 28.0 |
About Sumitomo Dainippon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sumitomo Dainippon Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sumitomo Dainippon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sumitomo Dainippon Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Sumitomo Pink Sheet
If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Stocks Directory Find actively traded stocks across global markets |